Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
olmesartan medoxomil, Quantity: 10 mg
Sandoz Pty Ltd
Olmesartan medoxomil
Tablet, film coated
Excipient Ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; hyprolose; purified water; hypromellose; titanium dioxide; iron oxide yellow; macrogol 4000
Oral
30
(S4) Prescription Only Medicine
OLMESARTAN SANDOZ is indicated for the treatment of hypertension.
Visual Identification: 10 mg tablet: Yellow film-coated, round, biconvex tablets debossed with 392 one one side, and L on the other side. Blister pack of 30.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2015-02-05
200320-Olmesartan Sandoz-pi Page 1 of 22 AUSTRALIAN PRODUCT INFORMATION OLMESARTAN SANDOZ (OLMESARTAN MEDOXOMIL) TABLETS 1. NAME OF THE MEDICINE Olmesartan medoxomil 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Olmesartan Sandoz contains the active ingredient olmesartan medoxomil. Olmesartan Sandoz is available for oral use as film-coated tablets containing 10 mg, 20 mg, or 40 mg olmesartan medoxomil. _List of excipients with known effect:_ Lactose monohydrate For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM 10 MG TABLET: Yellow film-coated, round, biconvex tablets debossed with 392 one one side, and L on the other side. 20 MG TABLET: Yellow film coated, round, biconvex tablets debossed with 323 on one side and L on the other side. 40 MG TABLET: Yellow film coated, oval shape, biconvex tablets debossed with L324 on one side and plain on the other side. 4. CLINICAL PARTICULARS 4.1. T HERAPEUTIC INDICATIONS Olmesartan Sandoz is indicated for the treatment of hypertension. 4.2. D OSE AND METHOD OF ADMINISTRATION DOSAGE _ADULTS _ Dosage must be individualised. The optimal recommended starting dose is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40 mg daily. In order to assist compliance, it is recommended that olmesartan medoxomil tablets be taken at about the same time each day. Twice-daily dosing offers no advantage over the same total dose given once daily. The antihypertensive effect of olmesartan medoxomil is substantially present within 2 weeks of initiating therapy and is maximal by about 8 weeks after initiating therapy. This should be borne in mind when considering changing the dose regimen for any patient. Hydrochlorothiazide therapy should be considered in those patients requiring additional blood pressure control beyond 40 mg daily. Olmesartan medoxomil may be administered with other antihypertensive agents. 200320-Olmesartan Sandoz Read the complete document